IKCC is a full member of the of the Management Board of CARE1 Pragmatic Clinical Trial, a European phase III multi-centre study of first-line treatment for metastatic kidney cancer. Coordinated from France and involving eight European countries, the study aims to help oncologists around the world select the best treatment combination for each kidney cancer patient using a biomarker.
IKCC has the role of representing the perspectives, insights and experiences of kidney cancer patients. Specifically, IKCC oversees patient-facing materials (including digital resources) to ensure patient needs are met and manages a Patient Advisory Board for the project.
The goal of CARE1 is to develop guidelines for the best standard of treatment based on the PD-L1 biomarker to improve kidney cancer treatment and outcomes. This program is supported by a European grant and is coordinated by Professor Laurence Albiges, Head of the Department of Oncology at Gustave Roussy Cancer Centre in France.
For more information about the CARE1 Pragmatic Clinical Trial, click here.